NTLA: Late-stage gene editing therapies for HAE and TTR advance, with FDA review and targeted launch plans
The company is advancing late-stage in vivo gene editing therapies for HAE and TTR, with FDA review for HAE underway and a targeted commercial strategy in place. Strong clinical data, robust financial planning, and strategic partnerships position the company for future pipeline expansion.Based on I…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.